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The effects of Lactobacillus 
plantarum on small intestinal 
barrier function and mucosal 
gene transcription; a randomized 
double-blind placebo controlled 
trial
Zlatan Mujagic1,2, Paul de Vos1,3, Mark V. Boekschoten1,4, Coen Govers1,5,  
Harm-Jan H. M. Pieters2, Nicole J. W. de Wit5, Peter A. Bron1,6, Ad A. M. Masclee2 & 
Freddy J. Troost1,2
The aim of this study was to investigate the effects of three Lactobacillus plantarum strains on in-vivo 
small intestinal barrier function and gut mucosal gene transcription in human subjects. The strains were 
selected for their differential effects on TLR signalling and tight junction protein rearrangement, which 
may lead to beneficial effects in a stressed human gut mucosa. Ten healthy volunteers participated 
in four different intervention periods: 7-day oral intake of either L. plantarum WCFS1, CIP104448, 
TIFN101 or placebo, proceeded by a 4 weeks wash-out period. Lactulose-rhamnose ratio (an indicator 
of small intestinal permeability) increased after intake of indomethacin, which was given as an artificial 
stressor of the gut mucosal barrier (mean ratio 0.06 ± 0.04 to 0.10 ± 0.06, p = 0.001), but was not 
significantly affected by the bacterial interventions. However, analysis in small intestinal biopsies, 
obtained by gastroduodenoscopy, demonstrated that particularly L. plantarum TIFN101 modulated 
gene transcription pathways related to cell-cell adhesion with high turnover of genes involved in tight- 
and adhesion junction protein synthesis and degradation (e.g. actinin alpha-4, metalloproteinase-2). 
These effects were less pronounced for L. plantarum WCFS1 and CIP104448. In conclusion, L. plantarum 
TIFN101 induced the most pronounced probiotic properties with specific gene transcriptional effects on 
repair processes in the compromised intestine of healthy subjects.
Impairment of intestinal barrier function has been implicated as an early event in the pathogenesis of various 
intestinal and systemic disorders. It may lead to increased permeation of substances present in the gut lumen, 
such as bacteria and their products (e.g. lipopolysaccharides), into the mucosal layer and may result in local and 
systemic inflammatory responses1–3. This process is assumed to play a role in the pathophysiology of organic 
gastro-intestinal (GI) disorders such as inflammatory bowel disease4–6, and celiac disease7, but also of functional 
GI disorders, such as irritable bowel syndrome8,9. Furthermore, it has been associated with systemic disorders, 
such as diabetes mellitus10, atopic eczema11, liver disease12, as well as the use of medication, such as non-steroidal 
anti-inflammatory drugs (NSAIDs)13,14. NSAIDs are frequently consumed worldwide but have also been used in 
research as a model to stress the intestinal mucosal layer and barrier function in healthy subjects15. Up to now, 
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no therapeutic agents have been developed that are able to successfully restore the intestinal mucosal barrier 
and thereby influence disease outcome16. Positive effects on intestinal barrier function have been attributed to 
probiotic bacteria17–23. However, further research is needed to prove these beneficial effects in humans and to 
gain further insight into the mechanisms through which live bacterial organisms improve the human gut barrier 
function24,25.
In a healthy intestinal homeostasis commensal non-pathogenic bacteria interact with host mucosa and 
thereby presumably co-regulate mucosal barrier function. Lactobacillus plantarum, a commensal bacterium pres-
ent in humans, has been reported to reinforce the intestinal barrier and to reduce intestinal permeability in ani-
mal studies18–20. In a previous study by our consortium, the administration of L. plantarum WCFS1 directly into 
the duodenum of healthy human subjects beneficially contributed to the organization of the epithelial tight junc-
tions17. Next to L. plantarum WCFS1, we have selected two more L. plantarum strains, i.e. CIP104448 (CIP48), 
and TIFN101 (in previous studies referred to as CIP104450), to be tested in the current study. They were selected 
based on research wherein these bacterial strains were shown to have differential effects in toll-like receptor 
(TLR) signalling in vitro and to affect both the innate and specific immune system both in vitro and in vivo26–28. 
Although it has recently been demonstrated in an in vitro model that TLR signalling is involved in regulation of 
the intestinal barrier function29, it is unknown whether these three L. plantarum strains have positive effects on 
intestinal mucosal barrier in human subjects after ingestion, or through which mechanisms these live bacterial 
organisms may improve the human gut barrier function.
We hypothesized that daily oral administration of L. plantarum WCFS1, CIP48, and TIFN101 over a 7-day 
period (i) will have positive effects on compromised (due to intake of NSAIDs) intestinal barrier function in 
healthy human subjects, with regard to intestinal permeability, tight junction protein- and gene expression, and 
furthermore (ii) will induce alterations in the transcription of pathways involved in mucosal structure and cell 
function, as measured in duodenal biopsy material.
Aim of the present randomized, double-blind, placebo-controlled trial was to assess the effects of oral intake 
of the three L. plantarum strains over a 7-day period on small intestinal permeability, duodenal epithelial tight 
junction protein expression and mucosal gene transcription, in healthy human subjects.
Results
Ten healthy volunteers, 7 female and 3 male, with the age between 19 and 48 years (mean 26.3 ± 10.1) and a BMI 
between 16 and 24 kg/m2 (mean 21.8 ± 2.40) were included in the trial and underwent four intervention periods 
in a double blind randomised cross over design (Fig. 1). None of the participants reported discomfort or possible 
side effects during the test and follow-up period, nor have we found any significant differences in the outcomes of 
the self-report questionnaires, i.e. GSRS and daily symptom diary, before and after supplementation or between 
the placebo and the three L. plantarum test periods (data not shown). One subject did not undergo two of the four 
gastroduodenoscopies (during the L. plantarum TIFN101 test period) due to anticipation of discomfort. These 
data were considered as missing during analyses.
Intestinal permeability. L/R ratio of the baseline test with indomethacin stressor (mean 0.098 ± 0.056) was 
significantly higher compared to baseline L/R ratio without stressor (0.058 ± 0.037, p < 0.001) (Fig. 2), particu-
larly due to a strong increase in urinary lactulose excretion. Comparing L/R ratio between these two time points 
per intervention period, the L/R ratio increased during three of the four periods (Table 1 and Suppl. Figure I). For 
the L. plantarum WCFS1 test period this difference was not statistically significant. Furthermore, there was no 
statistically significant difference between L/R ratios at baseline after the indomethacin induced stress compared 
to this ratio assessed after 7-day supplementation with either placebo or one of the three L. plantarum strains, 
measured after the indomethacin induced stress. This was also true for delta L/R ratio differences between test 
periods (Fig. 3).
Figure 1. Schematic representation of a test period. Three and one-day prior to start of supplementation 
period, small intestinal permeability (L/R ratio) was assessed; at day-3 without, and at day 0 with indomethacin 
induced mucosal stress. Subsequently, a 7-day supplementation period followed, with oral intake of placebo or 
one of the three L. plantarum strains twice a day. At day 7 the permeability test with intake of indomethacin was 
repeated and biopsies were obtained using flexible gastroduodenoscopy.
www.nature.com/scientificreports/
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Immunofluorescence labelling: ZO-1 and occludin expression. Immunofluorescent staining of the 
duodenal mucosa tissue samples showed expression of ZO-1 and occludin proteins at the apical part of epithelial 
cells, colocalized along the villous epithelium. Although the expression of both proteins seemed to increase after 
the interventions when compared to placebo (Fig. 4), the differences did not reach statistically significance.
Transcriptional responses of tight junction associated genes. Microarray analysis of single gene 
transcriptome with focus on the tight junctions and supporting proteins (Suppl. Table I) showed a significant 
down-regulation of the claudin 5 gene by L. plantarum WCFS1 (mean fold change (FC): − 1.168, p = 0.019) and 
the claudin 19 gene by CIP48 (− 1.146, p = 0.036), and a significant up-regulation of the actinin alpha 4 gene by 
Figure 2. Indomethacin significantly increases intestinal permeability. Study participants were subjected 
to a sugar-based permeability test. Ratio of lactulose and rhamnose (L/R ratio) was determined in 5 hr urine 
samples of subjects without indomethacin stressor (day-3) or with stressor (day 0) before intake of the 
permeability test. Mean ± SD of L/R ratio without stressor = 0.058 ± 0.037 and with stressor = 0.098 ± 0.056. 






After 7-day supplementation, 
with indomethacin stressor
Placebo 0.026 [0.016; 0.037] 0.060 [0.030; 0.076]* 0.079 [0.058; 0.123]*
L. plantarum WCFS1 0.023 [0.015; 0.055] 0.047 [0.026; 0.066] 0.076 [0.035; 0.164]**
L. plantarum CIP104448 0.032 [0.017; 0.051] 0.069 [0.026; 0.105]* 0.075 [0.053; 0.114]**
L. plantarum TIFN101 0.022 [0.018; 0.039] 0.057 [0.030; 0.078]* 0.065 [0.045; 0.133]**
Table 1.  Permeability test per intervention. L/R ratio presented as median [Q1; Q3]. Differences tested with 
related samples Wilcoxon signed rank test. *p < 0.05, **p < 0.01 vs. ‘Baseline, without indomethacin stressor’. 
No statistically significant differences were observed between ‘Baseline, with indomethacin stressor’ vs. ‘After 
7-day supplementation, with indomethacin stressor’.
Figure 3. The effect of three L. plantarum strains and placebo on L/R ratio. Delta L/R ratio: L/R ratio after 
supplementation and stressor minus L/R ratio before supplementation and stressor. Scatterplot with median 
line presented. No statistically significant difference found between test periods, tested with related samples 
Wilcoxon signed rank test.
www.nature.com/scientificreports/
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TIFN101 (1.105, p = 0.032). RT-qPCR (Suppl. Figure II) was conducted for five genes, which in line microarray 
data, showed no statistically significant differences for claudin 3, claudin 4, MLCK, ZO-1 and occludin gene tran-
scription between bacterial strains and placebo.
Transcriptional responses: Ingenuity Pathway Analysis. To further explore possible effects of the 
L. plantarum strains on the mucosal barrier, we focused on canonical pathways related to mucosal structure, 
enterocyte energy supply, DNA-repair, stress response and cell activity. All three interventions induced changes 
in transcriptional responses in the indomethacin stressed duodenal mucosa when compared to placebo.
TIFN101 demonstrated regulation of pathways involved in remodelling of the mucosal structure. 
Epithelial-mesenchymal transition pathway (Fig. 5), involved in disruption and remodelling of desmosomal 
adhesion, and pathways that might be involved in restructuring of cell-cell adhesions (i.e. macropinocytosis sig-
nalling pathway, Fig. 6) and cytoskeleton rearrangement (i.e. integrin signalling pathway, Fig. 7) were upregulated. 
Moreover, we observed a combined up-regulation of matrix metalloproteinase 2 (MMP2) gene (1.297, p = 0.006), 
involved in degradation of extracellular structures, and its inhibitors, so-called tissue inhibitors of metalloprotein-
ase (TIMP) 1 (1.362, p = 0.006), and TIMP3 (1.243, p = 0.028). TIFN101 also upregulated the muc2 gene (1.286, 
p = 0.031), encoding for the mucin 2 protein. Furthermore, the glutamate-ammonia ligase (GLUL) gene (1.155, 
p = 0.022), involved in glutamine biosynthesis pathways, was upregulated, which may enhance energy release 
based on glutamine biosynthesis of mucosal cells. On the other hand this strain downregulated expression of 
genes involved in the tricarboxylic acid (TCA) cycle II pathway (Suppl. Figure IIIa), which may lead to reduced 
adenosine triphosphate (ATP) production.
WCFS1 and CIP48 downregulated nitric oxide synthase 3 gene (NOS3) (− 1.113, p = 0.039 and − 1.162, 
p = 0.018, respectively), involved in cell-cell adhesion, and MMP9 (− 1.178, p = 0.045 and − 1.218, p = 0.025, 
respectively), involved in breakdown of the extracellular matrix. CIP48 upregulated genes related to inositol 
phosphates biosynthesis, components of the cytosolic side of the cell membrane, such as myotubularin related 
protein 9 (MTMR9) (1.132, p = 0.014), MTMR8 (1.182, p = 0.043), MTMR2 (1.131, p = 0.006), phospholipase-C 
β 4 (PLCB4) (1.131, p = 0.014), and protein tyrosine phosphatase, non-receptor type 2 (PTPN2) (1.187, p = 0.018).
WCFS1 demonstrated regulation of genes and pathways related to cell division processes and DNA repair 
(Suppl. Figure IIIb and c), with involvement of BRCA1 (1.225, p = 0.022) and BRCA2 genes (1.199, p = 0.018), 
and upregulation of protection of telomere1 (POT1) gene (1.161, p = 0.004). CIP48 showed similar effects, with 
upregulation of BRCA1 (1.182, p = 0.043) and 2 (1.199, p = 0.018) genes and a pathway involved in cell division 
Figure 4. Zonula occludens-1 (ZO-1) and occludin fluorescence intensity in duodenum mucosal tissue 
after immunofluorescent staining, expressed as area under the curve (AUC), after treatment with placebo 
or one of the three L. plantarum strains. 
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and DNA-repair (Suppl. Figure IIId). Finally, CIP48 also inhibited expression of the GADD45B gene (− 1.223, 
p = 0.034) in the glutathione-mediated detoxification pathway, involved in cell stress response, and the neuropep-
tide Y (NPY) gene (− 1.159, p = 0.022), a protein that influences the fat metabolism.
Figure 5. Epithelial-mesenchymal transition pathway, upregulated by L. plantarum TIFN 101 compared 
to placebo. Green and red coloured genes indicate down or upregulation, respectively. Grey indicates the 
regulation did not reach significance.
Figure 6. Macropinocytosis signalling pathway, upregulated by L. plantarum TIFN 101 compared 
to placebo. Green and red coloured genes indicate down or upregulation, respectively. Grey indicates the 
regulation did not reach significance.
www.nature.com/scientificreports/
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Discussion
In the current study we investigated the effects of oral intake of three L. plantarum strains over a 7-day period on 
small intestinal barrier function under a stressed condition, induced by intake of NSAIDs, in healthy volunteers. 
Small intestinal permeability was increased after intake of indomethacin, but was not significantly affected by any 
of the treatments. However, the different interventions did modulate gut mucosal gene transcription related to 
mucosal structure, enterocyte energy supply, DNA-repair, stress response and cell activity pathways, when com-
pared to placebo, revealing new insights into the mechanisms by which live potentially probiotic organisms may 
modulate human small intestinal mucosa.
Intake of indomethacin at baseline and after the intervention period resulted in a significant increase in small 
intestinal permeability, as reflected by the increased urinary excretion of lactulose versus rhamnose. This con-
firmed that the NSAID is a potent stressor of small intestinal barrier function, and that this model is well suited 
to investigate potential beneficial effects of bioactive substances in healthy individuals. The 7-day supplementa-
tion period of the different bacterial strains did not significantly affect small intestinal permeability. Previously, 
Karczewski et al. demonstrated that a continuous intraduodenal administration of L. plantarum WCFS1 over a 
6-hr period in healthy subjects (without intake of NSAIDs) increased tight junction-linked localisation of occlu-
din and ZO-1 proteins17. Our results do not confirm these findings which should be explained by pertinent dif-
ferences in design such as application of indomethacin as stressor and differences in administration of bacteria. 
The influence of indomethacin on epithelial barrier may have been too pronounced to detect beneficial functional 
effects induced by the bacterial interventions. However, also differences in route of administration (i.e. oral versus 
intraduodenal) and exposure time (i.e. 7 days versus 6 hours) may account for the observed difference between 
these studies.
Although the interventions did not affect indomethacin induced changes in small intestinal permeability, 
the three tested L. plantarum strains did influence intrinsic repair processes of the small intestinal mucosa on 
gene transcription level. Differential effects on transcription of genes and pathways involved in mucosal struc-
ture maintenance have been observed. The strongest modulatory effects in this respect were demonstrated by 
L. plantarum TIFN101 when compared to placebo. Intake of this bacterial strain influenced the transcriptional 
response related to the turnover of adhesion molecules and homeostasis of the mucus layer. This is exemplified 
by alterations of pathways involved in cytoskeleton rearrangement, and upregulation of genes such as actinin 
alpha 4, several MMP genes but also their inhibitors (TIMP genes). Moreover, the up-regulation of the macropi-
nocytosis signalling pathway, which is one of the mechanisms involved in disruption of intercellular contacts of 
adherens and tight junctions30,31, may lead to increased recycling of adhesive molecules. L. plantarum TIFN101 
also modulated genes that may be involved in inducing a shift of energy supply of the mucosal cells from oxidative 
phosphorylation (by TCA II pathway downregulation) towards glutamine production (by increased transcription 
of glutamine biosynthesis pathways). Glutamine is an important energy source for intestinal epithelial cells and 
it promotes cell differentiation and proliferation32. Moreover, glutamine deprivation in intestinal epithelial cells 
was associated with a loss of tight junction proteins which may lead to impaired paracellular permeability33. On 
the other hand, glutamine supplementation has been reported to reinforce the intestinal epithelial mucosal bar-
rier34,35. Therefore, the effect of L. plantarum TIFN101 on the glutamine biosynthesis pathways may be considered 
beneficial for the intestinal barrier function. Finally, the mucin 2 gene is upregulated by TIFN101. Mucin 2 is 
produced by the goblet cells and together with related mucin proteins is polymerized into insoluble mucus, which 
is an important part of the intestinal barrier36,37. As the number of goblet cells, and thereby mucin production, is 
increasing along the proximal to distal axis of the intestine, the effect of TIFN101 on intestinal barrier might also 
be stronger when it reaches more distal parts of the intestine.
Figure 7. Integrin signaling pathway, upregulated by L. plantarum TIFN 101 compared to placebo. Green 
and red coloured genes indicate down or upregulation, respectively. Grey indicates the regulation did not reach 
significance.
www.nature.com/scientificreports/
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L. plantarum WCFS1 showed some negative effects on the transcription of genes and pathways involved in 
mucosal barrier homeostasis, by downregulation of genes such as claudin 538 and NOS3. The latter gene is linked 
to maintenance of cytoskeletal proteins, e.g. α -tubulin, actinin and vimentin, and tight junction integral mem-
brane proteins, e.g. occludin39. Contradictory, L. plantarum WCFS1 downregulated MMP9 gene, which leads to 
inhibitory effects on breakdown of extracellular matrix40, suggesting beneficial effects of L. plantarum WCFS1 
supplementation on mucosal integrity. L. plantarum CIP48 demonstrated similar modest effects on gene tran-
scription. NOS3, MMP9, and claudin 19 genes were downregulated after the intervention. Furthermore, genes 
involved in inositol phosphates biosynthesis, important for cell membrane structure and membrane potential41, 
was upregulated by L. plantarum CIP48. Thereby, both strains, L. plantarum WCFS1 and CIP48, seem to be 
involved in maintaining a balance between enhancement and disruption of cell-cell adhesion and mucosal struc-
ture, with no direct functional consequences for intestinal permeability and tight junction protein expression.
We identified more mechanisms by which the three tested L. plantarum strains affect the human host on tran-
scriptome level. L. plantarum WCFS1 increased the transcription of genes such as BRCA1 and 2 and POT1, which 
are involved in cell division processes, DNA repair and telomere length regulation, suggesting that this bacterial 
strain may be involved in the enhancement of epithelial healing after indomethacin induced mucosal stress. The 
transcription of the NPY gene, which encodes for a neuro-hormone in the leptin signalling pathway was inhibited 
by L. plantarum CIP48. Antagonising NPY-ergic activity has been reported to reduce food intake42. However, no 
other effects on satiety related mechanisms were observed in the transcriptome analysis, and therefore the effects 
on satiety are probably minimal.
In summary, L. plantarum TIFN101 demonstrated regulation of genes and pathways involved in cell-cell 
adhesion and turnover of adhesion molecules. Furthermore, this strain seems to be able to induce gene transcrip-
tions involved in energy supply of the mucosal cells by affecting both oxidative phosphorylation- and glutamine 
production pathways. L. plantarum WCFS1 modulated the transcription of genes related to DNA repair, possibly 
based on mucosal tissue healing upon NSAID induced stress, and showed minor negative effects on gene tran-
scription related to mucosal structure. L. plantarum CIP48 demonstrated similar effects with respect to DNA 
repair mechanisms and minor positive effects on gene transcription and pathways related to mucosal structure. 
Overall our study demonstrates that the effect of bacterial supplementation on gene transcription is highly strain 
dependent and differs considerably within the same species. In the current study the transcriptome analysis was 
performed on duodenal biopsies. The effects might even be more pronounced or at least different in more dis-
tal parts of the intestine, as the mucosal function along the longitudinal axis of the intestine does vary. Further 
research is needed to investigate this hypothesis.
The cross-over design of the present study was preferred over a parallel arms design, to eliminate potential 
influences of inter-subject differences. An implicit potential disadvantage of a cross-over study is that previous 
interventions can influence effects of the next tests. To minimize such an influence a washout period of four weeks 
was chosen, and furthermore the order of the interventions was randomly assigned to each study participant.
In the present study the significantly regulated genes in the microarray data have not been remeasured by 
RT-qPCR, which may be a limitation with regard to the interpretation of the transcriptome data. In addition, 
future research should include in-vitro experiments to knock-down regulated genes and pathways in the pres-
ent study to test the intrinsic processes described above. The difference in dose between the three L. plantarum 
strains used may be a potential limitation of the study. The number of colony forming unites (cfu) is determined 
by bacterial survival during freeze-drying of the supplements, which differed per bacterial strain. Although a 
dose-response is possible, it is unlikely that differences observed between interventions are affected by the differ-
ence in doses used in the current study. Furthermore, the dose consumed by study subjects per shot was for all 
three bacterial strains in the range of 1010, which are dosages recommended to reach clinical usefulness43.
In previous studies L. plantarum WCFS1 was found to modulate multiple pathways in duodenal mucosa, 
related to lipid biosynthesis, cellular proliferation, cell-death and immune responses28,44. In the present study, 
we were able to confirm that L. plantarum WCFS1 does affect some similar pathways related to cell function; 
however, most transcriptional responses were dissimilar. The main difference between the current and pre-
vious research was the intake of indomethacin in the present study. While in previous research the effects of 
L. plantarum WCFS1 on healthy intestinal function were investigated, we assessed effect of the three bacterial 
strains on small intestinal mucosa under a stressed condition. Furthermore, Troost et al. administrated a load of 
L. plantarum WCFS1 using oro- and nasogastric catheters during 1 and 6 hours44, and Van Baarlen et al. admin-
istered supplements of the same bacterium by oral intake, and assessed effects after 6 hours28. Therefore, besides 
the difference in administration route44, we measured long term effects (i.e. after a 7-day administration period), 
compared to the short term effects (i.e. after 1 and 6 hours) assessed in the previous studies. Troost et al. demon-
strated that different supplementation periods lead to different transcriptional responses even between one and 
six hour administration of the bacteria44.
Comparison with other studies involving transcriptomics in the duodenum reveals that different bacterial 
species (i.e. L. acidophilus, L. casei, L. rhamnosus) induce very distinct gene-regulatory networks and pathways45, 
which were among others related to cell proliferation, hormonal regulation of blood pressure and ion home-
ostasis. These were not observed in the presented study, in which we used different L. plantarum strains. The 
described previous findings28,44,45 showed that the selection of the bacterial species as well as well as route and 
time period of administration of viable microbes may induce different effects on human health. In addition, 
taking into account these findings, our data indicate that also the selected bacterial strains and the presence of 
intestinal mucosal distress of the consumer may add to differences in effects of live bacteria on the intestinal 
mucosa. This pinpoints the need for further research in this area, but also underlines the care in selecting bacteria 
when testing potential management options of gastrointestinal disorders. The current study contributes to fur-
ther understanding of complex host-microbe interactions and human intestinal homeostasis, providing leads for 
future research in this field.
www.nature.com/scientificreports/
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Conclusion
Application of the NSAID indomethacin induced a profound increase in small intestinal permeability, which was 
not significantly affected by the intake of the three L. plantarum strains. However, the tested bacterial strains did 
modulate intrinsic repair processes on mucosal gene transcription level. L. plantarum TIFN101 demonstrated 
the most pronounced beneficial effects, by among others modulation of gene-transcriptions that are related to 
mucosal structure. L. plantarum WCFS1 and CIP48 induced more moderate transcriptional effects with respect 
to mucosal integrity. This illustrates the strain dependency with respect to inducing specific effects on gene tran-
scription in human intestinal mucosa.
Materials and Methods
The study protocol has been approved by the Maastricht University Medical Center+ Committee of Ethics, was 
in compliance with the Declaration of Helsinki (64th WMA General Assembly, Fortaleza, Brazil, 2013), and has 
been registered in the US National Library of Medicine (http://www.clinicaltrials.gov, NCT01456767).
Study participants. Healthy subjects were enrolled via public advertising, and were screened, involving a 
standardized general physical examination. All study participants gave written informed consent prior to inclu-
sion. Exclusion criteria were current GI symptoms, a history of severe disease or major abdominal surgery, use 
of any medication within 14 days or investigational drugs within 180 days prior to inclusion, blood donation 
within 3 months before the study period, pregnancy, lactation, obesity, smoking, use of drugs or excessive alcohol 
consumption, and known allergy/hypersensitivity towards intake of NSAIDs, sweeteners or pre- or probiotic 
supplements of any kind.
Sample size was determined using OpenEpi Sample Size Calculation for Cross-Sectional, Cohort, and Clinical 
Trials according to Fleiss46. Considering the primary outcome of the present cross-over study, which is lactulose 
and rhamnose recovery (the ratio is an indicator of intestinal permeability), based on previous studies22, taking 
into account an estimated effect size of 20% alteration in intestinal permeability between the interventions (three 
L. plantarum strains and placebo), a power of 80%, and a significance level of 5%, the study required eight com-
pleters. We included ten subjects in this study, anticipating drop-outs due to complexity and test/time burden for 
subjects.
Bacterial growth conditions and definition of placebo. The bacterial strains L. plantarum WCFS147,48, 
CIP48, and TIFN10126,27 were cultured overnight at 37 °C in Man, Rogosa and Sharpe (MRS) medium (Merck, 
New Jersey, USA), to obtain stationary-phase cultures. Maltodextrin and glucose were added to a final concen-
tration of 20% and 2% (wt/vol), respectively, to obtain bacterial preparations. Detailed protocols for culturing, 
harvesting, freeze-drying, storing, and viable count determining of Lactobacillus species has been published 
previously28. Placebo controls only contained maltodextrin and glucose at similar final concentrations as bacterial 
supplements, ensuring a similar appearance and taste. Encoded and non-transparent vials containing the supple-
ments were provided by NIZO Food Research (Ede, NL) to ensure the double-blind design.
Study design. This human study was designed and conducted as a randomized double-blind 
placebo-controlled cross-over trial. The effects of three potentially beneficial bacterial strains were investigated 
in each subject during four randomized test periods (Suppl. Table II). During each test period (Fig. 1), one of the 
following supplements has been orally ingested twice a day, during breakfast and dinner, for 7 consecutive days: 
L. plantarum WCFS1 (2.6 × 1010 colony forming units (cfu) per time point), L. plantarum CIP48 (2.4 × 1010 cfu/
time point), L. plantarum TIFN101 (5.9 × 1010 cfu/time point) or placebo. Each test period was followed by a 
washout period of four weeks. There was no standardised diet for the study participants; however, subjects were 
instructed to consume on the last day of each test period the same diet as they did on the last day of the first 
period.
Baseline permeability measurements were performed three days and one day prior to the intake of the sup-
plements, in the absence and presence of the intestinal mucosal barrier stressor indomethacin, respectively. 
Subsequently, subjects consumed one of the three L. plantarum strains or placebo for seven consecutive days. 
Thereafter, the permeability test with addition of indomethacin (but not the test without indomethacin) was 
repeated, whereupon the same day standard flexible gastroduodenoscopy was performed to obtain six tissue sam-
ples from the duodenum (D2 section), at approximately 15 cm distal to the pylorus. The mucosal biopsies were 
immediately flash frozen and used for RNA isolation followed by genome-wide microarray, and tight junction 
protein analysis. In line with previous research17,28,44 investigating effects L. plantarum strains, we focussed on the 
proximal small bowel, with minimal interference of other microbial interaction. This region of the small intestine 
is relatively accessible by means of endoscopy.
Possible side effects of the ingestion of the bacterial strains, adverse reactions to intake of indomethacin, and 
overall feelings of well-being were assessed using the validated gastrointestinal symptom rating scale (GRSR)49 
pre and post test period and during the intervention by a daily symptom diary9.
In vivo small intestinal permeability test. After an overnight fast, participants emptied their urinary 
bladder and consumed a drink (150 ml of tap water) containing 1 g lactulose (Centrafarm, Etten-Leur, the 
Netherlands) and 0.5 g L-rhamnose (Danisco, Copenhagen, Denmark). Participants were requested to remain 
fasted, with the exception of water intake, and to collect urine for 5 hours. Lactulose (disaccharide) can permeate 
the intestinal epithelial layer through the paracellular route and rhamnose (mono-saccharide) through the trans-
cellular route. The ratio in 0–5 h urine (L/R ratio) represents small intestinal permeability, and is used to minimize 
the effect of differences in gut motility and kidney function on the results50. During and two days prior to the test 
period, excessive physical exercise and consumption of alcohol were prohibited for the study participants. Three 
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days after this baseline permeability test and after the 7-day intervention period (Fig. 1), the test was repeated 
with ingestion of indomethacin, a NSAID, administered in two different dosages; i.e. 75 mg exactly 9 hours prior 
and 50 mg 1 hour prior to the intake of the sugars14. Levels of the urinary excreted sugar probes were measured 
under blinded conditions by isocratic ion-exchange high-pressure liquid chromatography with mass spectrome-
try (HPLC-MS) as described previously50.
RNA isolation, microarray processing and pathway analysis. Total RNA was isolated form snap 
frozen (in liquid nitrogen) duodenal biopsies, using 1 ml Trizol reagent (Invitrogen, Breda, NL). Subsequently 
it was purified using Qiagen RNeasy Micro kit (Qiagen, Venlo, NL). NanoDrop ND-1000 spectrophotometer 
(Isogen Life Science, De Meer, NL) was used for RNA quantification, and quality was checked by the Agilent 2100 
bioanalyzer (Agilent Technologies, Amsterdam, NL). Samples were obtained from ten subjects under four dif-
ferent conditions: L. plantarum WCFS, CIP48, TIFN101 and placebo. Off one subject two biopsies were missing 
yielding a total of 38 microarrays. Samples were used for further analyses in case of intact bands corresponding 
to 18S and 28S ribosomal subunits and in the absence of chromosomal peaks or RNA degradation products. 
Whole transcript cDNA synthesis of total RNA (100 ng) material was conducted using Ambion WT expression 
kit (Life Technologies, Bleiswijk, NL), and was labeled using the Affymetrix GeneChip WT Terminal Labelling 
Kit (Affymetrix, Santa Clara, CA). Next, samples were hybridized to human whole genome Affymetrix GeneChip 
Human Gene 1.1 ST arrays, washed, stained, and scanned on an Affymetrix GeneTitan instrument, according to 
the User Guide for Expression Array Plates (P/N 702933 Rev. 2).
Changes in gene expression were calculated as fold changes between placebo and the different L. plantarum 
strains by applying MADMAX51 for statistical comparison analyses for multiple ~omics experiments. Functional 
interpretation of gene signatures (pairwise IBMT p-value < 0.05) was performed using canonical pathway analy-
sis of Ingenuity Pathway Analysis (IPA) 3.0 (Qiagen Ingenuity Systems, Redwood City, CA). Canonical pathways 
demonstrating significant differential regulation (threshold p < 0.05) were considered for analysis. The datasets 
generated from microarray profiling experiments have been deposited to the publicly accessible database reposi-
tory Gene Expression Omnibus, and are available under accession number GSE74988.
Furthermore, gene transcription of tight junction proteins, i.e. claudin 3, claudin 4, myosin light chain kinase 
(MLCK), zonula occludens 1 (ZO-1) and occludin, in duodenal mucosal biopsies was also evaluated by RT-qPCR, 
as described previously52.
Expression of tight junction proteins in duodenal mucosa samples. Immunofluorescent staining 
for ZO-1 and occludin was performed on tissue-tek embedded frozen sections of the duodenal mucosa biopsy 
specimens, as described elsewhere53. Leica TCS SPE confocal laser-scanning microscope equipped with a 50-mW 
Argon laser and a 1-mW HeNe laser (Leica Microsystems, Wetzlar, Germany), was used to examine the slides, 
and ImageJ software to process and analyse the confocal images, as described previously54.
Data and statistical analysis. Statistical analysis was performed using IBM SPSS Statistics version 22.0 
(IBM Statistics for Windows, Armonk, NY). To compare all baseline L/R ratio measurements without and with 
indomethacin stressor (assessing the effect of the stressor irrespective of the test period) Linear Mixed Models 
were used to take into account multiple measurements (i.e. four) per subject. To compare the effect of the 7-day 
supplementation of the three Lactobacilli versus placebo on urinary L/R ratio, a delta score was calculated, i.e. 
the L/R ratio after 7-day supplementation and with stress test minus L/R ratio of baseline with stress test. Related 
samples Wilcoxon Signed Rank test was used to assess differences between the interventions versus placebo and 
to test differences in L/R ratio between the time points per test period. A two-sided p-value of < 0.05 was consid-
ered statistically significant.
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